An overview of topical antifungal therapy in dermatomycoses. A North American perspective

Drugs

Volumn 55, Issue 5, 1998, Pages 645-674

  Gupta, Aditya K ^a,d   Einarson, Thomas R ^b   Summerbell, Richard C ^c   Shear, Neil H ^c  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALLYLAMINE DERIVATIVE; AMOROLFINE; ANTIFUNGAL AGENT; BUTENAFINE; CICLOPIROX; POLYENE; PYRROLE DERIVATIVE;

CANDIDIASIS; CREAM; DERMATOMYCOSIS; DRUG FORMULATION; EPIDERMOPHYTON; HOST; HUMAN; INTRAVAGINAL DRUG ADMINISTRATION; MICROSPORUM; NORTH AMERICA; ORAL DRUG ADMINISTRATION; POWDER; REVIEW; TINEA CAPITIS; TINEA CORPORIS; TINEA CRURIS; TINEA VERSICOLOR; TOPICAL DRUG ADMINISTRATION; TRICHOPHYTON;

ADMINISTRATION, TOPICAL; ANTIFUNGAL AGENTS; DERMATOMYCOSES; HUMANS;

ANIMALIA; ARTHRODERMATACEAE; CANIS; EPIDERMOPHYTON; MALASSEZIA FURFUR; MAMMALIA; MICROSPORUM AUDOUINII; MICROSPORUM CANIS; TINEA; TINEA CRURIS; TRICHOPHYTON TONSURANS;

EID: 0031900078     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199855050-00004     Document Type: Review

References (447)

1. Weitzman I, Summerbell, RC. The dermatophytes. Clin Microbiol Rev 1995; 8: 240-59
2. Aly R. Ecology and epidemiology of dermatophyte infections. J Am Acad Dermatol 1944; 31: S21-5
3. Weilzman I, Kaue J. Dermatophytes and agents of superficial mycoses. In: Hausler WJ, Herrmann KL, Isenberg HD, et al., editors. Manual of clinical microbiology. 5th ed. New York: American Society for Microbiology. 1991: 601-6
4. Del Cas E, Vernes A. Parasitic adaptation of pathogenic fungi to mammalian hosts. Crit Rev Microbiol 1986; 13: 173-218
5. King RD, Khan HA, Foye JC, et al. Transterrin, iron and dermatophytes: I. Serum dermatophyte inhibitory component definitively identified as unsaturated transferrin. J Lab Clin Med 1975; 86: 204-12
6. Novick NL, Tapia L, Bottune EJ. Invasive Trichophyton rubrum infection in an immunocompromised host. Am J Med 1987; 82: 321-5
7. Elewski BE, Sullivan J. Dermatophytes as opportunisitc pathogens. J Am Acad Dermatol 1944; 30: 1021-2
8. Grossman ME, Pappert AS, Garzon MC, et al. Invasive Trichophyton rubrum infection in the imnunocoinpromised host: report of three cases. J Am Acad Dermatol 1995; 33: 315-8
9. Faergemann J, Gisslen H, Dahlberg E, et al. Trichophyton rubrum abcesses in immunocompromised patients. Acta Derm Venereol (Stockh) 1989; 69: 244-7
10. Lestringant GG, Lindley SK, Hillsdon-Smith J, et al. Deep dermatophytosis to T. rubrum and T. verrucosum in an immunosuppressed patient. Int J Dermatol 1988; 27: 707-9
11. Tsang P, Hopkins T, Jimenez-Lucho V. Deep dermatophytosis caused by Trichophyton rebrum in a patient with AIDS. J Am Acad Dermatol 1996; 34(6): 1090-1
12. Weitzman I, McGinnis MR, Padhye AA, et al. The genus Arthroderma and its later synonym Nannizzia. Mycotaxon 1986; 25: 505-18
13. Currah RS. Taxonomy of the Onygenales: Arthrodermataceae, Gymnoascaceae, Myxotrichaceae, and Onygenaceae. Mycotaxon 1985; 24: 1-216
14. Stern RS. The epidemiology of cutancous disease. In: Fitzpatrick TB, Eisen AZ, Wolff K, et al., editors. Dermatology in general practice., New York: McGraw Hill, 1993: 7-13
15. Anonymous. Prevalence, morbidity, and cost of dermatological diseases. J Invest Dermatol 1979; 73: 395-401
16. Anonymous. Infections. J Invest Dermatol 1979; 73: 452-9
17. Ajello L. Geographic distribution and prevalence of the dermatophytes. Ann NY Acad Sci 1960; 89: 30-8
18. Katoh T, Sano T, Kagawa S. Isolations of dermatophyte from clinically normal scalps in M. canis infections using the hairbrush method. Mycopathologia 1990; 112: 23-5
19. Klokke AH, Purushotham AG. Sundaraju D. Mass treatment of non-fluorescent tinea capitis in an orphanage in India, trial with a low griseofulvin dose using a modified brush-sampling technique. Trop Geogr Med 1966; 18: 305-9
20. Mackenzie DWR. 'Hairbrush diagnosis' in detection and eradication of non-flourescent scalp ringworm. BMJ 1963; 2: 363-5
21. Hubbard TW. de Triquet JM. Brush-culture method for diagnosing tinea capitis. Pediatrics 1992; 90: 416-8
22. Rasmussen JE. Cutaneous fungus infections in children. Pediatr Rev 1992; 13: 152-6
23. Davey KG, Campbell OK, Warnock DW. Mycological techniques. J Clin Pathol 1996; 49: 95-9
24. Suarez SM, Silvers DN, Scher RK, et al. Histologic evaluation of nail clippings for diagnosing onychomycosis. Arch Dermatol 1991; 127: 1517-9
25. Daniel CR III. The diagnosis of nail fungal infection. Arch Dermatol 1991; 127: 1566-7
26. Gupta AK, Scher RK, De Doncker P. Current management of onychomycosis: an overview. Dermatol Clin 1997; 15: 121-35
27. Zaias N, Taplin D. Improved preparation for the diagnosis of mycologic diseases. Arch Dermatol 1966; 93: 608-9
28. Elewski BE. Clinical pearl: diagnosis onychomycosis. J Am Acad Dermatol 1995; 32: 500-1
29. Robinson BE. Padhye AA. Collection, transport and processing of clinical specimens. In: Wentworth BB. editor. Diagnostic procedures for mycotic and parasitic infections. Washington, DC: American Public Health Association. 1988: 11-32
30. Taplin D, Zaias N, Rebell G, et al. Isolation and recognition of dermatophytes on a new medium (DTM). Arch Dermatol 1969; 99: 203-9
31. Rebell G, Taplin D. Dermatophytes, their recognition and identification. Coral Gables (FL): University of Miami Press. 1970
32. Fischer JB, Kane J. The laboratory diagnosis of dermatophytosis complicated with Candida albicans. Can J Microbiol 1974; 20: 167-82
33. Kligman AM, Mescon H, deLamater ED. The Hotchkiss-Mcmanus stain for the histopathologic diagnosis of fungus disease. Am J Clin Pathol 1951; 21: 86-91
34. Piérard GE, Arrese JE, De Doncker P, et al. Present and potential diagnostic techniques in onychomycosis. J Am Acad Dermatol 1996; 34: 273-7
35. Calderone RA. Immunoregulation of dermatophytosis. Crit Rev Microbiol 1989; 16: 338-68
36. Jones H. Immune response and host resistance of humans to dermatophyte infection. J Am Acad Dermatol 1993; 28: s12-8
37. Blake JS, Dahl MV, Herron MJ, et al. An immunoinhibitory cell wall glycoprotein (Mannan) from Trichophyton rubrum. J Invest Dermatol 1991; 96: 657-61
38. Hay RJ. Chronic dermatophyte infections: I. Clinical and mycological features. Br J Dermatol 1982; 106: 1-7
39. Dahl MV. Suppression of immunity and inflammation by products produced by dermatophytes. J Am Acad Dermatol 1993; 28: S19-23
40. Sharma V, Hall JC, Knapp JF, et al. Scalp colonization by Trichophyton tonsurans in an urban pediatric clinic. Arch Dermatol 1988; 124: 1511-3
41. Babel DE, Baughman SA. Evaluation of the adult carrier state in juvenile tinea capitis caused by trichophyton. J Am Acad Dermatol 1989; 21: 1209-12
42. Shah PC, Krajden S, Kane J, et al. Tinea corporis caused by Microsporum canis: report of a nosocomial outbreak. Eur J Epidemiol 1988; 4: 33-8
43. Snider R, Landers S, Levy ML. The ringworm riddle: an outbreak of Microsporum canis in the nursery. Ped Infect Dis J 1993; 12: 145-8
44. Sulzberger MB, Baer RL. Some recent advances in dermatological mycology. In: Sulzberger MB, Baer RL, editors. Year book of dermatology and syphilology. Chicago: Year Book Publishers, 1955: 7-33
45. Taplin D. Superficial mycoses. J Invest Dermatol 1976; 67: 177-81
46. Jones HE. Ketoconazole in the management of fungal disease. In: Levine HB, editor. Current therapies for mycotic diseases. Auckland: ADIS Press, 1982: 14-24
47. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview: part I. J Am Acad Dermatol 1994; 30: 677-98
48. Degreef H. The treatment of superficial skin infections caused by dermatophytes. Curr Top Med Mycol 1992; 4: 189-206
49. Rogers SCF, Burrows D, Neill D. Percutaneous absorption of phenol and methyl alcohol in magenta paint B.P.C. Br J Dermatol 1978; 98: 559-60
50. Fisher DA. Castellani's paint. Arch Dermatol 1979; 115: 675
51. Hay RJ. The current status of antimycotics in the treatment of local mycoses. Acta Derm Venereol (Stockh) 1986; 121: 103-8
52. Arnold HL. Castellani's paint without fuchsin. Arch Dermatol 1979; 115: 1287
53. Fisher AA. Irritant and toxic reactions to phenol in topical medications. Cutis 1980; 26: 363-4
54. Leyden JJ, Kligman AM. Aluminum chloride in the treatment of symptomatic athlete's foot. Arch Dermatol 1975; 111: 1004-10
55. Chren M-M, Bickers DR. Dermatological pharmacology. In: Gilman AG, Rall TW, Nies AS, et al., editors. The pharmacological basis of therapeutics. US: McGraw-Hill, 1993: 1572-91
56. Smith EB, Powell RF, Graham JL, et al. Topical undecylenic acid in tinea pedis: a new look. Int J Dermatol 1977; 16: 52-6
57. Lyddon FE, Gundersen K, Maibach HI. Short chain fatty acids in the treatment of dermatophytoses. Int J Dermatol 1980; 19: 24-8
58. Bennett JE. Antimicrobial agents. Antifungal agents. In: Gilman AG,. Rall TW, Nies AS, et al., editors. The pharmacological basis of therapeutics. US: McGraw-Hill, 1993: 1165-81
59. Hernanz ADP, Vicente SD, Ramos FM, et al. Randomized comparative clinical trial of itraconazole and selenium sulfide shampoo for the treatment of pityriasis versicolor. Rev Infect Dis 1987; 9: S121-7
60. Hersle K. Selenium sulphide treatment of tinea versicolor. Acta Derm Venereol (Stockh) 1971; 51: 476-8
61. Albright SD, Hitch JM. Rapid treatment of tinea versicolor with selenium sulfide. Arch Dermatol 1966; 93: 460-2
62. Sánchez JL, Torres VM. Double-blind efficacy study of selenium sulfide in tinea versicolor. J Am Acad Dermatol 1984; 11 (2): 235-7
63. Danby FW, Maddin WS, Margesson LJ, et al. A randomized, double-blind, placebo-controlled trial of ketoconazole 2% shampoo versus selenium sulfide 2.5% shampoo in the treatment of moderate to severe dandruff. J Am Acad Dermatol 1993; 29: 1008-12
64. Sánchez JL, Torres VM. Selenium sulfide in tinea versicolor: blood and urine levels. J Am Acad Dermatol 1984; 11: 238-41
65. Ketoconazole shampoo for dandruff [editorial]. Med Lett Drugs Ther 1994; 36: 68
66. Allen HB, Honig PJ, Leyden JJ, et al. Selenium sulfide: adjunctive therapy for tinea capitis. Pediatrics 1982; 69: 81-3
67. Brauer EW, Opdyke DL, Burnett CM. The antiseborrheic qualities of zinc pyrithione (zinc pyridine-2-thiol-l-oxide) in a cream vehicle. J Invest Dermatol 1966; 47: 174
68. Brauer EW. Antisehorrheic qualities of zinc pyrithione in a cream vehicle: 111. Clinical experience in pityriasis capitis (dandruff, seborrheic dermatitis of the scalp). Cutis 1969; 5: 723
69. Faergemann J, Fredriksson T. An open trial of the effect of a zinc pyrilhione shampoo in tinea versicolor. Cutis 1980; 25: 667, 669
70. Fredriksson T, Faergemann J. Double-blind comparison of a zinc pyrilhione shampoo and its shampoo base in the treatment of tinea versicolor. Cutis 1981; 31: 436-7
71. Tinver lotion and other topical preparations for tinea versicolor [editorial]. Med Lett 1965: 74-5
72. Manna VK, Pearse AD, Marks R. The effect of povidone-iodine paint on fungal infection. J Int Med Res 1984; 12: 121-3
73. Bamford JTM. Treatment of tinea versicolor with sulfur-salicylic shampoo. J Am Acad Dermutol 1983; 8: 211-3
74. Bamford JTM. Tinea versicolor treatment. Arch Dermatol 1974; 110: 956
75. Montes LF, Oakes RA, Pert P, et al. Topical griseotulvin in tinea versicolor: a double-blind study. J Am Acad Dermatol 1991; 25 (4): 726-8
76. Prestia AE. Topical benzoyl peroxide for the treatment of tinea versicolor. J Am Acad Dermatol 1983; 9: 277-8
77. Mills OH, Klignian AM. Tretinoin in tinea versicolor. Arch Dermatol 1974; 110: 638
78. Faergemann J, Fredriksson T. Propylene glycol in the treatment of tinea versicolor. Acta Derm Venereol (Stockh) 1974; 60: 92-3
79. Goldsmith LA. Propylene glycol. Int J Dermatol 1978; 17: 703-5
80. Faergemann J, Swanbeck G. Treatment of onychomycosis with a propylene glycol-urea-lactic acid solution. Mycoses 1988; 32: 526-40
81. Kligman AM. Dermatologic uses of urea. Acta Derm Venereol (Slockh) 1937; 37: 155
82. Swanbeck G. A new treatment of ichthyosis and other hyperkeralotic conditions. Acta Derm Venereol (Stockh) 1970; 48: 123
83. Ashton H, Frenk E. Stevenson CJ. Urea as a topical agent. Br J Dermatol 1970; 84: 194
84. Kuntz IDJ, Brassfield TS. Hydration of macromolecules: II. Effects of urea on protein hydration. Arch Biochem Biophys 1971; 142: 660
85. Grice K, Sattar H, Baker H. Urea and retinoic acid in ichthyosis and their effect on transepidermal water loss and water holding capacity of stratum corneum. Acta Derm Venereol (Stockh) 1973; 53: 114
86. Farber EM, South DA. Urea ointment in the nonsurgical avulsion of nail dystrophies. Cutis 1978; 22: 689-92
87. South DA, Farber EM. Urea ointment in the nonsingical avulsion of nail dystrophies - a reappraisal. Cutis 1980; 25: 609-12
88. Buselmeier TJ. Combination urea and salicylic acid ointment nail avulsion in nondystrophic nails: a follow-up observation. Cutis 1980; 25: 397-405
89. Hay RJ, Roberts DT, Doherly VR, et al. The topical treatment of onychoniycosis using a new combined urea/imidazole preparation. Clin Exp Dermatol 1988; 13: 164-7
90. Hardjoko FS, Widyanto S, Singgih I, et al. Treatment ol onychomycosis with a bifonazole-urea combination. Mycoses 1990; 33: 167-71
91. Torres-Rodríguez JM, Madrenys N, Nicolás MC. Non-traumatic topical treatment of onychomycosis with urea associated with bifonazole. Mycoses 1991; 34: 499-504
92. Roberts DT, Hay RJ, Doherty VR, et al. Topical treatment of onychomyeosis using bifonazole 1%urea 40% paste. Ann NY Acad Sci: 586-7
93. Nolting S. Non-traumatic removal of the nail and simultaneous treatment ol onychomycosis. Dermatologica 1984; 169: 117-20
94. Bonifaz A, Guzman A, Garcia C, et al. Efficacy and safety of bifonazole urea in the two-phase treatment of onychomycosis. Int J Dermatol 1995; 34 (7): 500-3
95. Ishii M, Haniada T, Asai Y. Treatment of onychomycosis by ODT therapy with 20% urea ointment and 2% tolnaftate ointment. Dermatologica 1983; 167: 273-9
96. White MI, Clayton YM. The treatment of fungus and yeast infections of nails by the method of chemical removal. Clin Exp Dermatol 1982; 7: 273-6
97. Rollman O. Treatment of onychomyeosis by partial nail avulsion and topical miconazole. Dermatologica 1982; 165: 54-61
98. Ramadan W, Mourad B, Ibrahim S, et al. Oil of bitter orange: new topical antitungal agent. Int J Dermatol 1996; 35: 448-9
99. Budavari S. Oil of bittet orange. In: Bndavari S, Maryadele J, Ann S, el al., editors. The Merck Index: an encyclopedia of chemicals, drugs, and biologicals. 11th ed. Rahway (NJ): Merck and Co., Inc, 1989: 1072-8
100. 6Cl. a metabolic product of Penicillium griseofulvin Dierck. Biochem J 1939; 33: 240
101. Gentles JC. Experimental ring-worm in guinea pigs: oral treatment with griseofulvin. Nature 1958; 182: 476
102. Blank H, Roth FJJ. The treatment of dermatomycoses with orally administered griseofulvin. Arch Dermatol 1959; 79: 259
103. Blank H. Commentary: treatment of dermatomycoses with griseofulvin. Arch Dermatol 1982; 118: 835-6
104. Korting HC. Schäfer-Korting M. Is tinea unguium still widely incurable? Arch Dermatol 1992; 128: 243-8
105. Martin AR. The systematic and local treatment of experimental dermatophytosis with griseofulvin. J Invest Dermatol 1959; 32: 525
106. Goldman L, Preston RH, Schwarz J. Topical griseofulvin therapy of that which is called tinea pedia. Acta Derm Vencreol (Stockh) 1959; 39: 454-60
107. Höfer W, Hönemann W, Koch E. Zur behandlung der Dermatomykosen mit Gricin-Salbe. Dtsch Gesundheitw 1968; 23: 1370
108. Wozniak KD, Friedrich E, Janik G. Griseofulvin-Salbendehandlung superficiller Trichophytien. Mykosen 1970; 13: 427
109. Arievich AM, Ziserman VE. Experience of topical application of griseofulvin for treatment of some mycotic lesions of the skin. Vestn Dermatol Venerol 1972; 46: 82
110. Levine HB, Cobb JM, Friedman RH. Griseofulvin in DMSO, penetration into guinea-pig skin and clinical findings in feline ringworm. Sabouraudia 1971; 9: 43
111. Stoughton RB, Fritsch W. Influence of dimelhylsulphoxide (DMSO) on human percutaneous absorption. Arch Dermatol 1964; 90: 512
112. Munro DD, Stoughlon RB. Dimethylacetamide (DMAC) and dimcthylformamide (DMFA) effect on percutaneous absorption. Arch Dermatol 1965; 92: 585
113. Knight AG. The activity of various topical griseofulvin preparations and the appearance of oral griseofulvin in the stratum corneum. Br J Dermatol 1974; 91: 49-55
114. Abdel-Aal H, El-Shazli M, Saleh AM. Topically applied griseofulvin in the treatment of superficial dermatomycoses in Egypt. J Int Med Res 1977; 5: 382
115. Macasaet EN, Pert P. Topical (1%) solution of griseofulvin in the treatment of tinea corporis. Br J Dermatol 1991; 124: 110-1
116. Zarowny DP, Rogers RS, Tindall JP. Evaluation of the effectiveness of griseofulvin, tolnaftate and placebo in the topical therapy of superficial dermatophytoses. J Invest Dermatol 1975; 64: 268-72
117. Epstein WL, Shah VP, Jones HE, et al. Topically applied griseofulvin in prevention and treatment of Trichophyton mentagrophytes. Arch Dermatol 1975; 111: 1293-7
118. Wallace SM, Shah VP, Epstein WL, et al. Topically applied antifungal agents: percutaneous penetration and prophylactic activity against Trichophyton mentagrophytes infection. Arch Dermatol 1977; 113: 1539-42
119. Aly R, Bayles CI, Oakes RA, et al. Topical griseofulvin in the treatment of dermatophytes. Clin Exp Dermatol 1994; 19: 43-6
120. Montes LF, Oakes RA, Pert P, et al. Topical griseofulvin in tinea versicolor: a double-blind study. J Am Acad Dermatol 1991; 25: 726-8
121. Dunne M, Flood M, Herxheimer A. Clioquinol: availability and instructions for use. J Antimicrob Chemother 1976; 2: 21-9
122. Clifford Rose F, Gawel M. Clioquinol neurotoxicity: an overview. Acta Neurol Scand 1984; 70: 137-45
123. Traveler's warning: entero-violorm [editorial]. Med Lett Drugs Ther 1975; 17: 105-6
124. Stohs SJ, Ezzedeen FW, Anderson AK. Percutananeous absorption of iodochlorhydroxyquin in humans. J Invest Dermatol 1984; 82: 195-8
125. Fischer I, Hartvig P. Skin absorption of 8-hydroxyquinolines. Lancet 1977; 1: 603
126. Bickers DR, Hazen PG, Lynch WS. Antifungal and anliyeast agents. In: Azamoff DL, editor. Clinical pharmacology of skin disease. New York: Churchill Livingstone, 1984: 163-88
127. Battistini F, Bolivar C, Zaias N, et al. Clinical antifungal activity of thiabendazole. Arch Dermatol 1974; 109: 695-9
128. Robinson HJ, Phares HF, Graessle OE. Antimycotic properties of Ihiabendazole. J Invest Dermatol 1964; 42: 479-81
129. Blank H, Rebell G. Thiabendazole activity against the fungi of dermatophytosis, mycetoma and chromomycosis. J Invest Dermatol 1965; 44: 219-20
130. Sorensen LJ, Robinson HJ. Activity of thiabendazole against Trichophyton mentagrophytes in guinea pigs. Antimicrob Agents Chemother 1964; 4: 742-5
131. Stone OJ, Ritchie EB, Willis CJ. Thiabendazole in dimethyl sulfoxide for tinea nigra palmaris. Arch Dermatol 1966; 93: 241-2
132. Noguchi T, Kaji A, Igarashi Y, et al. Antitrichophyton activity of naphthiomates. Antimicrob Agents Chemother 1962: 259-67
133. Ryder NS, Frank I, Dupont M-C. Ergosterol biosynthesis inhibition by the thiocarbamate antifungal agents tolnaftate and tolciclale. Antimicrob Agents Chemother 1986; 29: 858-60
134. Barrett-Bee KJ, Lane AC, Turner RW. The mode of antifungal action of tolnaftate. J Med Vet Mycol 1986; 24: 155-60
135. Robinson HM, Raskin J. Tolnaftate, a potent topical antifungal agent. Arch Dermatol 1965; 91: 372-6
136. Weinstein MJ, Oden EM, Moss E. Antifungal properites of tolnaftate in vitro and in vivo. Antimicrob Agents Chemother 1964; 3: 595-601
137. Roberts SOB, Champion RH. Treatment of ringworm infections with tolnaftate ointment. Practitioner 1967; 199: 797-8
138. Alban J. Tolnaftate in superficial fungus infections. Am J Dis Child 1965; 110: 624-7
139. Gomez EC, Huntley AC, Isseroff R, et al. Efficacy of tolciclate solution in patients with tinea pedis. Clin Ther 1986; 8 (6): 694-9
140. Cuce LC, Contijo Assuncao BF, Medawar LG, et al. Tolciclate versus miconazole. a double-blind trial in patients with dermatomycosis. J Int Med Res 1980; 8: 144-7
141. de Carneri I, Monti G, Bianchi A, et al. Tolciclate against dermatophytes. Arzneimittel Forschung 1976; 26: 769-72
142. Hermann HW. Clinical efficacy studies of haloprogin, a new topical antimicrobial agent. Arch Dermatol 1972; 106: 839-42
143. Carter VH. A controlled study of haloprogin and tolnaftate in tinea pedis. Curr Ther Res 1972; 14: 307-10
144. Katz R, Cahn B. Haloprogin therapy for dermatophytc infections. Arch Dermatol 1972; 106: 837-8
145. VanDersarl JV, Sheppard RH. Clotrimazole vs haloprogin treatment of tinea cruris. Arch Dermatol 1977; 113: 1233-5
146. Clayton YM, Gange RW, Macdonald DM, et al. A clinical double-blind trial of topical haloprogin and miconazole against superficial fungal infections. Clin Exp Dermatol 1979; 4: 65-73
147. Carter VH, Olansky S. Haloprogin and nystatin therapy for cutaneous candidiasis. Arch Dermatol 1974; 110: 81-2
148. Rudolph RI. Allergic contact dermatitis caused by haloprogin. Arch Dermatol 1975; 111: 1487-8
149. Moss HV. Allergic contact dermatitis due to halotex solution. Arch Dermatol 1974; 109: 572
150. Berlin AR, Miller OF. Allergic contact dermatitis from ethyl sehacate in haloprogin cream. Arch Dermatol 1976; 112: 1563-4
151. Medoff G, Kobayashi GA. The polyenes. In: SpellerDCE, edition Antifungal chemotherapy. Chichester: John Wiley & Sons, 1980: 3-33
152. Hazen EL, Brown R. Two antifungal agents produced by a soil actinomycete. Science 1950; 112: 423
153. Hazen EL, Brown R. Nystatin. Ann NY Acad Sci 1960; 89: 258-66
154. Dixon PN, Warin RP, English MP. Alimentary Candida albicans and napkin rashes. Br J Dermatol 1972; 86: 458-62
155. Coskey RJ. Contact dermatitis due to nystatin. Arch Dermatol 1971; 103: 228
156. Wasilewski C. Allergic contact dermatitis from nystatin. Arch Dermatol 1970; 102: 216-7
157. de Groot A, Conemans JMH. Nystatin allergy: petrolatum is not the optimal vehicle for patch testing. Dermatol Clin 1990; 8: 153-5
158. Natamycin for keratomycosis [editorial]. Med Lett Drugs Ther 1979; 21: 79-80
159. Abrams BB, Hänel H, Hoehler T. Ciclopirox olamine: a hydroxypyridone antifungal agent. Clin Dermatol 1991; 9: 471-7
160. Abruzzo GK, Fromtling RA, Turnbull TA. Effects of bifonazole, fluconazole, itraconazole, and terbinafine on the chemiluminescence response of immune cells. J Antimicrob Chemother 1987; 20: 61-8
161. Kligman AM, Bogaert H, Cordero C, et al. Evaluation of cicloprox olamine cream for the treatment of tinea pedis: multicenter, double-blind comparative studies. Clin Ther 1985; 7: 409-17
162. Aly R, Bagatell FK, Dittmar W, et al. Ciclopirox olamine lotion 1%: bioequivalence to ciclopirox olamine cream 1% and clinical efficacy in tinea pedis. Clin Ther 1989; 11: 290-303
163. Bogaert H, Cordero C, Ollague W, et al. Multicentre double-blind clinical trials of ciclopirox olamine cream 1% in the treatment of tinea corporis and tinea cruris. J Int Med Res 1986; 14: 210-6
164. Lassus A, Nolting KS, Savopoulos C. Comparison of cicloprox olamine 1% cream with cicloprox 1%-hydrocortisone acetate 1% cream in the treatment of inflamed superficial mycoses. Clin Ther 1988; 10: 594-9
165. Cullen SI, Frost P, Jacobson C, et al. Treatment of tinea versicolor with a new antifungal agent, ciclopirox olamine cream 1%. Clin Ther 1985; 7: 574-83
166. Jue SG, Dawson GW, Brogden RN. Ciclopirox olamine 1% cream: a preliminary review of its antimicrobial activity and therapeutic use. Drugs 1985; 29: 330-41
167. Bagatell FK, Bogaert H, Cullen SI, et al. Evaluation of a new antifungal cream, ciclopirox olamine 1% in the treatment of cutaneous candidosis. Clin Ther 1985; 8: 41-8
168. Altmeyer P, Nolting S, Kuhlwein A, et al. Effect of fenticonazole spray in cutaneous mycosis: a double-blind clinical trial versus ciclopiroxolamine spray. J Int Med Res 1990; 18: 61-7
169. Corte M, Jung K, Linker U, et al. Topical application of a 0.1% ciclopiroxolamine solution for the treatment of pityriasis versicolor. Mycoses 1989; 32: 200-3
170. Ceschin-Roques CG, Hanel H, Pruja-Bougaret SM, et al. Ciclopiroxolamine nail lacquer 8%: in vitro penetration through nails and in vitro effect on pig skin. Skin Pharmacol 1991; 4: 89-94
171. Baran R, Virahen R, Bougaret S, et al. Effect of an 8% ciclopirox anlifungal lacquer in onychomycosis: a multicenler, double-blind clinical trial versus systemic ketoconazole [abstract]. Second Congress of the European Academy of Dermatology and Venereology; 1941: Athens. 182
172. Ulbricht H, Wörz K. Therapy of onychomycosis due to moulds with ciclopirox nail lacquer. Mycoses 1994; 37: 97-100
173. Gupta AK. Amorolfine: an overview. Drugs Today 1995; 31; 145-53
174. Haria M, Bryson HM. Amorolfine: a review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. Drugs 1995; 49: 103-20
175. Zaug M, Bergstraesser M. Amorolfine in the treatment of onychomycoses and dermatomycoses (an overview). Clin Exp Dermatol 1992; 17: 61-70
176. Polak AM. Preclinical data and mode of action of amorolfine. Clin Exp Dermatol 1992; 17 Suppl. 1:8-12
177. Roncari G, Ponclle Ch. Zumbrunnen R, et al. Percutaneous absorption of amorolfine following a single topical application of an amorolfine cream formulation. Clin Exp Dermatol 1992; 17: 33-6
178. Nolting S, Reinel D, Semig G, et al. Amorolline spray in the treatment of foot mycoses (a dose-finding study). Br J Dermatol 1993; 129: 170-4
179. Franz TJ. Absorption of amorolfine through human nail. Dermatology 1992; 184: 18-20
180. Polak A. Kinetics of amorolfine in human nails. Mycoses 1993; 36: 101-3
181. Franz TJ. Percutaneous absorption, on the relevance of in-vitro duta. J Invest Dermatol 1975; 64: 190-5
182. Zaug M. Amorolfine nail lacquer: clincal experience in onychomycosis. J Eur Acad Dermatol Venereol 1995; 4 Suppl. 1: S23-30
183. Rigopoulos D, Katsambas A, Antoniou C, et al. Discoloration of the nail plate due to the misuse of amorolfine 5% nail lacquer. Acta Derm Venereol (Stockh) 1996; 76: 83-4
184. Nussbaumer P, Dorfstätter G, Grassberger MA, et al. Synthesis and structure-activity relationships of phenyl-substiluted benzylamine antimycotics: a novel benzylbenzylamine antifungal agent for systemic treatment. J Med Chem 1993; 36: 2115-20
185. Maeda T, Taknse M, Ishibashi A, et al. Synthesis and antifungal activity of butenafine hydrochloride (KP-363), a new benzylamine antifungal agent. Yakugaku Zasshi 1991; 111: 126-37
186. Fukushiro R, Urabe H, Kagawa S, et al. Butenafine bydrochloride. a new antifungal agent: clinical and experimental study. In: Yamaguchi H, Kobayashi GS, Takahashi H, editors. Recent progress in antifungal therap. New York: Marcel Dekker, 1992: 147-57
187. Brennan B, Leyclen JJ. Overview of topical therapy for common superficial fungal infections and the role of new topical agents. J Am Acad Dermatol 1997: 36: S3-8
188. Tschcn E, Elewski B, Gorsulowsky DC, Pariser DM. Treatment of interdigital tinea pedis with a 4-week once daily regimen of butenafine hydrochloride 1% cream. J Am Acad Dermatol 1997; 36: S9-14
189. Savin R, De Villez RL, Elewski B, et al. One-week therapy with twice-daily butenafine 1% cream versus vehicle in the treatment of tinea pedis: a multicenter, double-blind trial. J Am Acad Dermatol 97; 36: S15-9
190. Lesher JL, Babel DE, Stewart DM, et al. Butenafine 1% cream in the treatment of tinea cruris: a multicenter, vehicle-controlled, double-blind trial. J Am Acad Dermatol 1997; 36: S20-4
191. Greer DL. Weiss J. Rodriguez DA, et al. A randomized trial to assess once-daily topical treatment of tinea corporis with butenafine, a new antifungal agent. J Am Acad Dermatol 1497; 37: 231-5
192. Fromtling RA. Overview of medically important antifungal azole derivatives. Clin Microbiol Rev 1988; 1: 187-217
193. Lackner TE. Clissold SP. Bifonazole: a review of its antimicrobial activity and therapeutic use in superficial mycoses. Drugs 1989; 38: 204-25
194. Plempel M, Regel E, Büchel KH. Antimycotic efficacy of bifonazole in vitro and in vivo. Drug Res 1983; 33: 517-24
195. Patzschke K, Ritter W, Siefert HM, et al. Pharmacokinetic studies following syslemic and topical administration of radiolabeled bifonazole in man. Arzneimittel Forschung 1983; 33: 745-50
196. Stettendorf S. Bifonazole - a synopsis of clinical trials worldwide. Dermatologica 1984; 169: 69-76
197. Wheatley D, Richardson MD, Scott EM. Tinea infections treated with bifonazole gel. Mycoses 1988; 31: 471-5
198. Galimberti RL, Belli L, Negroni R, et al. Treatment of tinea pedis interdigitalis with bitonale, 1% gel. Dermatologica 1984; 169: 107-10
199. Smith EB, Tschen E. Treatment of interdigital tinea pedis and tinea versicolor with bifonazole 1% solulion applied once daily. In: Fromtling RA, editor. Recent trends in discovery, development and evaluation of antifungal agents. Barcelona: JR Prous Science Publishers, 1987: 407-14
200. Goffe BS. Response of tinea corporis/cruris and tinea versicolor to once-a-day topical treatment with bifonazole cream - a safety and efficacy study. In: Fromtling RA, editor. Recent trends in the discovery, development and evaluation of antifungal agents. Barcelona: JR Prous Science Publishers. 1987: 423-9
201. Mora RG, Greer DL, Jolly HW. Prospective analysis of the response of tinea versicolor to topical application of Bifonazole 1% cream. In: Fromtling RA, editor. Recent trends in the discovery, development, and evaluation of antifungal agents. Barcelona: JR Prous Science Publishers. 1987: 415-21
202. Soyinka F. Bifonazole in the treatment of fungal skin infections in the tropics: a clinical and mycolugical study. Cur Med Res Opin 1987; 10: 390-6
203. Del Palacio Hernanz A, López Gómez S, Iglesias Diez L. Short course bifonazole therapy in pityriasis versicolor. Clin Exp Dermatol 1987; 12: 270-1
204. Chu AC. Comparative clinical trial of bifonazole solution versus selenium sulphide shampoo in the treatment of pityriasis versicolor. Dermatologica 1984; 169 Suppl. 1: 81-6
205. Mora RG, Greer DL. Comparative efficacy and tolerance of 1% bifonazole cream and bifonazole cream vehicle in patients with tinea versicolor. Dermatologica 1984; 169: 87-92
206. Aste N, Pau M, Cordaro CI, et al. Double-blind study with fenticonazole or bifonazole lotions in pityriasis versicolor. Int J Clin Pharm Res 1988: 8: 271-3
207. Hay RJ, Adriaans B, Midgley G, et al. A single application of bifonazole 1% lotion in pityriasis versicolor. Clin Exp Dermatol 1987; 12: 315
208. Galimberti R, Belli L, Gatti JC, et al. An open, multicentre assessment of the effectiveness of bifonazole in the treatment of tinea (pityriasis) versicolor. Pharmatherapeutica 1985; 4: 109-12
209. Galimberti RL, Bonino M, Flores V, et al. Ultra-short topical treatment of pityriasis versicolor with 2.5% bifonazole cream. Clin Exp Dermatol 1993; 18: 25-9
210. Hernàndez-Pèrez E. A comparison between two different regimens of monthly application with bifonazole spray 1% in pityriasis versicolor. Int J Dermatol 1990; 29: 438-40
211. Segal R, David M, Ingber A, et al. Treatment with bifonazole shampoo for seborrhea and seborrheic dermatitis: a randomized, double-blind study. Acta Derm Venereol (Stockh) 1992; 72: 454-5
212. Walker KAM, Braemer AC, Hitt S, et al. 1-[4-(4-chlorophenyl)-2-(2,6 dichlorophenylthio)-n-butyl]-1H-imidazole nitrate, a new potent antifungal agent. J Med Chem 1978; 21: 840-3
213. Droegemueller W, Adamson GD, Brown D, et al. Three day treatment with butoconazole nitrate for vulvovaginal candidiasis. Obstet Gynecol 1984; 64: 530-4
214. Tatum DM, Eggleston M. Butoconazole nitrate. Infect Control Hosp Epidemiol 1988; 9 (3): 122-4
215. Hajman AJ. Vulvovaginal candidosis: comparison of 3-day treatment with 2% butoconazole nitrate cream and 6-day treatment with 1% clotrimazole cream. J Int Med Res 1988; 16: 367-75
216. Bradbeer CS. Mayhew SR, Barlow D. Butoconazole and miconazole in treating vaginal candidiasis. Genitourin Med 1985; 61: 270-2
217. Plempel M, Bartmann K, Büchel H, et al. Bay B5097, a new orally applicable antifungal substance with broad spectrum activity. Antimicrob Agents Chemother 1969; 9: 271-4
218. Holt RJ, Newman RL. Laboratory assessment of the antimycotic drug clotrimazole. J Clin Pathol 1972; 25: 1089-97
219. Plempel M, Bartmann K, Büchel KH, et al. Antimycotic properties of clotrimazole. Postgrad Med J 1974 Jul; 50 Suppl. 1: 11-2
220. Oberste-Lehn H. Ideal properties of a modern antifungal agent - the therapy of mycoses with clotrimazole. Postgrad Med J 1974 Jul: 50 Suppl. 1: 51-3
221. Polemann G. Clinical experience in the local treatment of dermatomycoses with clotrimazole. Postgrad Med J 1974 Jul: 50 Suppl. 1: 54-6
222. Clayton YM, Connor BL. Clinical trial of clotrimazole in the treatment of superficial fungal infections. Postgrad Med J 1974 Jul: 50 Suppl. 1: 66-8
223. Zaias N, Battistini F. Superficial mycoses. Arch Dermatol 1977; 113: 307-8
224. Ipp MM, Boxall L, Gelfand EW. Clotrimazole: intermittent therapy In chronic mucocutaneous candidiasis. Am J Dis Child 1977; 131: 305-7
225. Male O. A double-blind comparison of clotrimazole and tolnaftate therapy of superficial dermatophytoses. Postgrad Med J 1974 Jul; 50 Suppl. 1: 75-6
226. Naftifine Podiatric Study Group. Naftifine cream 1% versus clotrimazole cream 1% in the treatment of tinea pedis. J Am Podiatr Med Assoc 1990; 80: 314-8
227. Fredriksson T. Topical treatment of superficial mycoses with clotrimazole. Postgrad Med J 1974 Jul; 50 Suppl. 1: 62-4
228. Gip L. The topical therapy of pityriasis versicolor with clotrimazole. Postgrad Med J 1974 Jul; 50 Suppl. 1: 59-60
229. Clayton R, Du Vivier A, Savage M. Double-blind trial of 1% clotrimazole cream and whitfield ointment in the treatment of pityriasis versicolor. Arch Dermatol 1977; 113: 849-50
230. Clayton YM, Connor BL. Comparison of clotrimazole cream, Whitfield's ointment and nystatin ointment for the topical treatment of ringworm infections, pityriasis versicolor, erythrasma and candidiasis. Br J Dermatol 1973; 89: 297-303
231. Shadomy S. In vivo studies with bayb 5097. Antimicrob Agents Chemother 1970: 169-74
232. Ogata M, Matsumoto H, Hamada Y, et al. 1-[1-[2-[(3-Chlorobenzyl)oxy]phenyl]vinyl]-1H-imidazole hydrochloride, a new potent antifungal agent. J Med Chem 1983; 26: 768
233. Meinicke K, Michel G. Croconazole: a new broad spectrum agent in the treatment of fungal skin infections. Int J Clin Pharm Res 1994; 14: 139-48
234. Michel G. Croconazole. Drugs Today 1993; 29: 307
235. Kuhlwein A, Busch T. Tinea inguinalis und Tinea pedis: Croconazol versus Bifonazol in der Lokaltherapie. Therapiewoche 1990; 40: 1643
236. Beierdörffer H, Michel G, Kehr K. Croconazole in the treatment of tinea pedis. Mycoses 1995; 38: 501-7
237. Shono M, Hayashi K, Sugimoto R. Allergic contact dermatitis from croconazole hydrochloride. Contact Derm 1989; 21: 225-7
238. Font E, Freixes J, Juive J. Perfil del nuevo antimicotico topico eberconazol. Rev Iberoam Micol 1994; 11: 58-9
239. Tomas JM, Camprubi S, Merino S, et al. Inhibition of two imidazole antimycotics, eberconazole and clotrimazole, by different components of Candida albicans serotype B membrane protoplasts. Int J Antimicrob Agents 1993; 3: 61-4
240. del Palacio A, Cuetara S, Rodriguez Noriega A. Topical treatment of tinea corporis and tinea cruris with eberconazole (WAS 2160) cream 1% and 2%: a phase II dose-finding pilot study. Mycoses 1995; 38: 317-24
241. Godefroi EF, Heeres J, Van Cutsem J, et al. The preparation and antimycotic properties of derivatives of 1-phenethyl-imidazole. J Med Chem 1969; 12: 784-91
242. Heel RC, Brogden RN, Speight TM, et al. Econazole: a review of its antifungal activity and therapeutic efficacy. Drugs 1978; 16: 177-201
243. Schaefar H, Stüttgen G. Absolute concentrations of an antimycotic agent, econazole, in the human skin after local application. Drugs 1976; 26: 432-5
244. Fredriksson T. Treatment of dermatomycoses with topical econazole and clotrimazole. Curr Ther Res 1979; 25: 590-4
245. Kates SG, Myung KB, McGinley KJ, et al. The antibacterial efficacy of econazole nitrate in interdigital toe web infections. J Am Acad Dermatol 199; 22: 583-6
246. Cullen SI. Millikan LE, Mullen RH. Treatment of tinea pedis with econazole nitrate cream. Cutis 1986; 7: 388-9
247. Daily AD, Kramer KJ, Rex IH, et al. Econazole nitrate (Spectazole) cream, 1 percent: a topical agent for the treatment of tinea pedis. Cutis 1985; 35: 278-9
248. Grigoriu D, Pallarés JL. Follow-up study after more than one year including 100 patients treated for superficial mycoses. Dermatologica 1980; 160: 62-8
249. Cullen SI, Rex HI, Thome EG. A comparison of a new antifungal agent. 1% econazole nitrate (Spectazole®) cream versus 1% clotrimazole cream in the treatment of intertriginous candidosis. Curr Ther Res 1984; 35: 606-9
250. Wong ESM, Hay RJ, Clayton YM, et al. Comparison of the therapeutic effect of ketoconazole tablets and econazole lotion in the treatment of chronic paronychia. Clin Exp Dermatol 1984; 9: 489-96
251. Hira SK, Din SN, Patel JS. Econazole 1% in the treatment of pityriasis versicolor in Zambia. J Am Acad Dermatol 1985; 12: 580-1
252. Vicik GJ, Mendiones M, Qinones CA, et al. A new treatment for tinea versicolor using econazole nitrate 1.0 percent cream once a day. Cutis 1984; 33: 570-1
253. Brenner M. Efficacy of twice-daily dosing of econazole nitrate 1% cream for tinea pedis. J Am Podiatr Med Assoc 1990; 81: 583-7
254. Mackie RM. Topical econazole in cutaneous fungal infections. Practitioner 1980; 224: 1311-3
255. Nardi D, Cappelletti R, Catto A, et al. New alpha-aryl-beta,N-imidazolylethyl benzyl and naphthylmethyl ethers with antimycotic and antibacterial activity. Arzneimittel Forschung 1981; 31: 2123
256. Tajana R, Cappelletti R, Leonardi A, et al. Synthesis and antimycotic activity of alpha-aryl-beta, N-imidazoly-alkyl benzyl ethers. Arzneimittel Forschung 1981; 31: 2121
257. Costa AL. In vitro antimycotic activity of fenticonazole (REC 15-1476). Mykosen 1982; 25: 47
258. Veronese M, Barzaghi D, Bertoncini A. Antifungal activity of fenticonazole in experimental dermatomycosis and candidiasis. Arzneimittel Forschung 1981; 31: 2137
259. Veronese M, Barzaghi D, Bertoncini A, et al. Fenticonazole: a new antifungal imidazole derivative, In vitro and in vivro antimycotic activity. Mykosen 1984; 27: 192
260. Veronese M, Salvaterre M, Barzaghi D. Fenticonazole, a new imidazole derivative with antibacterial and antifungal activity: in vitro study. Arzneimittel Forschung 1981; 31: 2133
261. Clerico R, Ribuffo A. Efficacy and tolerance of fenticonazole versus miconazole cream. Int J Clin Pharm Res 1987; 7: 77-81
262. Veronese M, Bertoncini A, Monici Preti P. Evaluation of the skin retention time of imidazole derivatives. Mykosen 1987; 30: 386-90
263. Jung EG, Bisco A, Azzollini E, et al. Fenticonazole cream once daily in dermatomycosis, a double-blind controlled trial versus bifonazole. Dermatologica 1988; 177: 104-8
264. Leiste D, Braun W, Fegeler W, et al. A double-blind clinical trial of fenticonazole (2%) spray versus naftifine (1%) spray in patients with cutaneous mycoses. Curr Med Res Opin 1989; 11: 567-75
265. Aste N, Pau M, Zucca M, et al. Clinical experience with fenticonazole 2% formulation in the treatment of dermatomycoses and pityriasis versicolor. Int J Clin Pharm Res 1987; 7: 503-6
266. Athow-Frost TAM, Freeman K, Mann TAN, et al. Clinical evaluation of fenticonazole cream in cutaneous fungal infections: a comparison with miconazole. Curr Med Res Opin 1986; 10: 107-16
267. Kokoschka EM, Niebauer G, Molinari M, et al. Treatment of dermatomycoses with topical fenticonazole and econazole. Mykosen 1986; 29: 45-50
268. Sartani A, Cordaro CI, Panconesi E. A multicenter trial with a new imidazole derivative, fenticonazole, in superficial fungal skin infections. Curr Ther Res 1988; 43: 1194-203
269. Bartolí J, Alguero M, Boncompte E, et al. Synthesis and antifungal activity of a series of difluorotrityl-imidazoles. Arzneimittel Forschung 1992; 42: 832-5
270. Garcia Rafanell J, Dronda MA, Merlos M, et al. In vitro and in vivo studies with flutrimazole, a new imidazole derivative with antifungal activity. Arzneimittel Forschung 1992; 42: 836-40
271. Izquierdo I, Bayes M, Jané J, et al. Local and systemic tolerance of flutrimazole skin creams following single and repeated topical application in healthy volunteers. Arzneimittel Forschung 1992; 42: 859-60
272. 14C]flutrimazole following single topical application in normal and scarified skin of healthy volunteers. Arzneimittel Forschung 1992; 42: 861-3
273. Alomar A, Videla S, Delgadillo J, et al. Flutrimazole 1% dermal cream in the treatment of dermatomycoses: a mutticentre, double-blind, randomized, comparative clinical trial with bifonazole 1% cream. Dermatology 1995; 190: 295-300
274. Del Palacio A, Cuétara S, Izquierdo I, et al. A double-blind, randomized comparative trial: flutrimazole 1% solution versus bifonazole 1% solution once daily in dermalomycoses. Mycoses 1995, 38: 395-403
275. Binet O, Soto-Melo J, Delgadillo J, et al. Flutrimazole 1% dermal cream in the treatment of dermatomycoses: a randomized,multicentre, double-blind, comparative clinical trial with 1% clotrimazole cream. Mycoses 1994; 37: 455-9
276. Kessler H-J. Mikrobiologische Untersuchungen mit Isoconazolnitrat, einem breitspektrum-Antimykoticum aus der Gruppe der Imidazol-derivative. Arzneimittel Forschung 1979; 29: 1344-51
277. Dykes PJ, Marks R, Tauber U. The retention of isoconazole in the skin after once or twice daily application of 1% isoconazole nitrate cream (Travogen) over a 14-day period. Clin Exp Dermatol 1986; 11: 365-70
278. Gugnani HC, Akpata LE, Gugnani MK, et al. Isoconazole nitrate in the treatment of tropical dermatomycoses. Mycoses 1994; 37: 39-41
279. Täuber U, Rach P, Lachnit U. Persistence of isoconazole in vaginal secretion after single application. Mykosen 1984; 27: 97-101
280. Walther M. Feldstudie die Einmaltherapie von Vaginal-mykosen mit Isoconazolnitrat. Praxis 1982; 71: 152-6
281. Heeres J. Backx LJJ, Mostmans JH, et al. Antimycotic imidazoles: 4. Synthesis and antifungal activity of ketoconazole, a new potent orally active broad-spectrum antifungal agent. J Med Chem 1983; 22: 1003-5
282. Thienpont D, Van Cutsem J, Van Gervan F, et al. Ketoconazole - a new broad spectrum orally active antimycotic. Experientia 1979; 35: 606-7
283. Odds FC, Milne LJR, Gentles JC, et al. The activity in vitro and in vivo of a new imidazole antifungal ketoconazole. J Antimicrob Chemother 1980; 6: 97-104
284. Ketoconazole 2% cream product information [editorial]. In: Physicians desk reference. 51st ed. Montvale (NJ): Medical Economics Company Inc., 1997: 1344-5
285. Odds FC, Webster CE, Abbott AB. Antifungal relative inhibition factors: BAY 1-9139, bifonazole, butoconazole, isoconazole, itraconazole (R 51211), oxiconazole, Ro 14-4767/002, sulconazole, terconazole and vibunazole (BAY n-7133) compared in vitro with nine established antifungal agents. J Antimicrob Chemother 1984; 14: 105-14
286. Lester M. Ketoconazole 2 percent cream in the treatment of tinea pedis, tinea cruris, and tinea corpons. Cutis 1995; 55: 181-3
287. Greer D, Jolly HW. Topical ketoconazole treatment of cutaneous candidiasis. J Am Acad Dermatol 1988; 18: 748-9
288. Ford GP, Farr PM, Ive FA, et al. The response of seborrhoeic dermatitis to ketoconazole. Br J Dermatol 1984; 111: 603-7
289. Leyden JJ. McGinley KJ, Kligman AM. Role of microorganisms in dandruff. Arch Dermatol 1976; 112: 333
290. Shuster S. The aetiology of dandruff and the mode of action of therapeutic agents. Br J Dermatol 1984; 3: 235-42
291. Skinner RB, Noah PW, Taylor RM, et al. Double-blind treatment of seborrheic dermatitis with 2% ketoconazole cream. J Am Acad Dermatol 1985; 12: 852-6
292. Stratigos JD, Antoniou C, Katsambas A, et al. Ketoconazole 2% cream versus hydrocortisone 1% cream in the treatment of seborrheic dermatitis: a double-Wind comparative study. J Am Acad Dermatol 1988; 19: 850-3
293. Katsambas A, Antoniou CH, Frangouli E, et al. A double-blind trial of treatment of seborrhoeic dermatitis with 2% ketoconazole cream compared with 1% hydrocortisone cream. Br J Dermatol 1989; 121: 353-7
294. Carr MM, Pryce DM, Ive FA. Treatment of seborrhoeic dermatitis with ketoconazole: I. Response of seborrhoeic dermatitis of the scalp to topical ketoconazole. Br J Dermatol 1987; 116: 213-6
295. Green CA, Fair PM, Shuster S. Treatment of seborrheic dermatitis with ketoconazole: II. Response of seborrheic dermatitis of the face, scalp and trunk to topical ketoconazole. Br J Dermatol 1987; 116: 217-21
296. Ive FA. An overview of experience with ketoconazole shampoo. Br J Clin Pracl 1991; 45: 279-84
297. McGrath J, Murphy GM. The control of seborrhoeic dermatitis and dandruff by antipityrosoral drugs. Drugs 1991; 41: 178-84
298. Cauwenbergh G, De Doncker P, Schrooten P, et al. Treatment of dandruff with a 2% ketoconazole scalp gel: adouble-blind placebo-controlled study. Int J Dermatol 1986; 25 (8): 541
299. Peter RU, Richarz-Barthauer U. Successful treatment and prophylaxis of scalp seborrhoeic dermatitis and dandruff with 2% ketoconazole shampoo: results of a multicentre. double-blind, placebo-controlled trial. Br J Dermatol 1995; 132: 441-5
300. Brown M, Evans TW, Poyner T, et al. The role of ketoconazole 2% shampoo in the treatment and prophylactic management of dandruff. J Dermatol Treat 1990; 1: 177-9
301. Fair PM, Shusler S. Treatment of seborrhoeic dermatitis with topical ketoconazole. Lancet 1984; 11: 1271-2
302. Taieb A, Legrain V, Palmier C, et al. Topical ketoconazole for infantile seborrhoeic dermatitis. Dermatologica 1990; 181: 26-32
303. Savin RC, Horwitz SN. Double-blind comparison of 2% ketoconazole cream and placebo in the treatment of tinea versicolor. J Am Acad Dermatol 1986; 15: 500-3
304. Meisel C. Treatment of tinea versicolor with 2% ketoconazole emulsion vs. climbazole and placebo: a double blind study. Z Hautkr 1991; 66: 415-8
305. Rekacewicz I, Guillaume JC, Benkhraba F, et al. Étude en double insu contre excipient du kétoconazole lotion moussante à 2 p. 100 en application unique dans le traitement du Pityriasis versicolor. Ann Dermatol Venereol 1990; 117: 709-11
306. Ketoconazole product monograph. Mississauga (Ont): Janssen Pharmaceutica Inc., 1995 May
307. Niwano Y, Tabuchi T, Kanai K, et al. Short-term topical therapy of experimental tinea pedis in guinea pigs with lanoconazole, a new imidazole antimycotic agent. Antimicrob Agents Chemother 1995; 39: 2353-5
308. Niwano Y, Seo A, Kanai K, et al. Therapeutic efficacy of lanoconazole, a new imidazole antimycotic agent, for experimental cutaneous candidiasis in guinea pigs. Antimicrob Agents Chemother 1994; 38: 2204-6
309. Ohmi T, Konaka S, Uchida M, et al. Antifungal activity of the new agent lanoconazole in two tinea models. Arzneimittel Forschung 1991; 41: 847-51
310. Oka H, Niwano Y, Ohmi T, et al. Therapeutic efficacy of lanoconazole in formulations of clinical use on experimental dermatophytosis in guinea pigs. Arzneimittel Forschung 1992; 42 (I): 345-9
311. Takahashi H. New topical imidazoles under development in Japan: TJN-318 (NND-318). Evaluation of antifungal activities and the result of clinical open study on dermatomycoses. In: Yamaguchi H, Kohayashi GS, Takahashi H, et al., editors. Recent progress in antifungal chemotherapy. New York: Marcel Dekker. Inc., 1991: 103-12
312. Godefroi EF, Heeres J, Van Custem J, et al. The preparation and antimycotic properties of derivatives of 1-phenethylimidazole. J Med Chem 1969; 12: 784-91
313. Van Cutsem JM, Thienpont D. Miconazole: a broad-spectrum antimycotic agent with antibacterial activity. Chemotherapy 1972; 17: 392-404
314. Odds FC, Abbott Ab, Pye G, et al. Improved method for estimation of azole antifungal inhibitory concentrations against Candida species, based on azole/antibiotic interactions. J Med Vet Mycol 1986; 24: 305-11
315. Yamaguchi T, Hiratani T, Plempel M. In vitro studies of a new imidazole antimycotic, bifonazole, in comparison with clotrimazole and miconazole. Arzneimittel Forschung 1983; 33: 546-51
316. Heel RC, Brogden RN, Pakes GE, et al. Miconazole: a preliminary review of its therapeutic efficacy in systemic fungal infections. Drugs 1980; 19: 7-30
317. Mandy SJ, Garrott MTC. Miconazole treatment for severe dermatophytoses. JAMA 1974; 230 (I): 72-5
318. Fulton JE. Miconazole therapy for endemic fungal disease. Arch Dermatol 1975; 113: 596-8
319. Ongley RC. Efficacy of topical miconazole treatment of tinea pedis. Can Med Assoc J 1978; 119: 353-4
320. Nolting S, Strauss WB. Treatment of impetigo and ecthyma: a comparison of sulconazole with miconazole. Int J Dermatol 1988; 27: 716-9
321. Tanenbaum L, Anderson C, Rosenberg MJ, et al. 1% sulconazole cream v 2% miconazole cream in the treatment of tinea versicolor. Arch Dermatol 1984; 120: 216-9
322. Pitcher DG, Noble WC, Seville RH. Treatment of erythrasma with miconazole. Clin Exp Dermatol 1979; 4: 453-6
323. Mesquita-Guimaraes J, Ramos S, Tavares MR, et al. A double-blind clinical trial with a lotion containing 5% benzoyl peroxide and 2% miconazole in patients with acne vulgaris. Clin Exp Dermatol 1989; 14: 357-60
324. Ogawa M, Matsuda H, Eto H, et al. Synthesis and antifungal activities of a series of (1,2-distributed vinyl) imidazoles. Chem Pharm Bull 1991; 39: 2301-7
325. Tsuboi R, Matsumoto T, Ogawa H, et al. Hyperkeratotic chronic tinea pedis treated with neticonazole cream. Int J Dermatol 1996; 35: 371-3
326. Asaoka T, Kawahara R, Iwasa A, et al. Antifungal activity of S5717, a new imidazole antimycotic: I In vitro antimicrobial activity. Chemotherapy 1990; 38: 753-68
327. Thile KL, Zirngibl MH, Pfeinninger M, et al. Antimykotisch wirksame Imidazolylalkene: syntheses und Rontogenstrukturanalyse von Omoconazol. Helv Chim Acta 1987; 70: 441
328. Zirngibl L, Fischer J, Jahn U, et al. Structure-activity relationships of 2-(1H-imidazol-1-yl) vinyl ethers. Ann NY Acad Sci 1988; 544: 63-73
329. Gip L. The in vitro determination of lingering antimycotic effect of two 1% omoconazole-nitrate cream formulations following single topical application. Mycoses 1988; 31: 155-8
330. Nishiyama Y, Itoyama T, Yamaguchi H. Ultrastructural alterations of Candida albicans induced by a new imidazole antimycotic omoconazole nitrate. Microbiol Immunol 1997; 41: 395-402
331. Mixich G, Thiele K. Ein Beitrag zur stereospezifischen Synthese von antimykotisch wirksamen Imidazolyloximäthern. Oxiconazol-nitrat (Sgd 301-76), ein neues Breitbandantimykotikum. Arzneimittel Forschung 1979; 29: 1510-3
332. Jegasothy BV, Pakes GE. Oxiconazole nitrate: pharmacology, efficacy, and safety of a new imidazole antifungal agent. Clin Ther 1991; 13: 126-41
333. Gebhart RJ, Espinel-Ingroff A, Shadomy S. In vitro susceptibility studies with oxiconazole (Ro 13-8996). Chemotherapy 1984; 30: 244-7
334. Polok A. Oxiconazole, a new, imidazole derivative. Arzneimittel Forschung 1982; 32: 17-24
335. Ramelet AA, Walker-Nasir E. One daily application of oxiconazole cream is sufficient for treating dertmatomycoses. Dermatologica 1987; 175: 293-5
336. Polak A. Antifungal activity of four antifungal drugs in the cutaneous retention time test. Sahouraudia 1984; 22: 501-3
337. Ellis CN, Gammon WR, Goldfarb MT, et al. A placebo-controlled evaluation of once-daily versus twice-daily oxiconazole nitrate (1%) cream in the treatment of tinea pedis. Curr Ther Res 1989; 46: 269-76
338. Pariser DM, Pariser RJ. Oxiconazole nitrate lotion. 1 percent: an effective treatment for tinea pedis. Cutis 1994; 54: 43-4
339. Gip L. Comparison of oxiconazole (Ro 13-8996) and econazole in dermatophytoses. Mykosen 1984; 27: 295-302
340. Wagner W. Comparison of clinical efficacy and tolerability of oxiconazole one dose vs. two doses daily. Mykosen 1986; 29: 280-4
341. Gouveia DC, da Suva CJ. Oxiconazole in the treatment of vaginal candidiasis: single dose versus 3-day treatment with econazole. Pharmatherapeutica 1984; 3: 682-5
342. Gugnani HC, Ideyi C, Gugnani MK. Oxiconazole in the treatment of tropical dermatomycoses. Curr Ther Res 1993; 54(1): 122-5
343. Raga M, Palacín C, Castelló JM, et al. Fur J Med Chem 1986; 21: 329
344. Farré M, Ugena B, Badenas JM, et al. Pharmacokinetics and tolerance of sertaconazole in man after repealed percutaneous administration. Arzneimittel Forschung 1992; 42: 752-4
345. Umbert P, Nasarre J, Bello A, et al. Phase 11 study of the therapeutic efficacy and safety of the new antimycotic sertaconazole in the treatment of superficial mycoses caused by Candida albicans. Arzneimittel Forschung 1992; 42: 757-60
346. Nasarre J, Umbert P, Herrero E, et al. Therapeutic efficacy and safely of the new antimycotic sertaconazole in the treatment of pityriasis versicolor. Arzneimittel Forschung 1992; 42: 764-7
347. Van Esso D, Fajo G, Losada I, et al. Sertaconazole in the treatment of pediatric patients with cutaneous dermatophyte infections. Clin Ther 1995; 17: 264-9
348. Yoshida H, Kasuga O, Yamaguchi T. Studies on antifungal activities of sulconazole: I. In vitro antimicrobial activity. Chemotherapy (Tokyo) 1984; 32: 477-84
349. Yoshida H, KasugaO, Yamaguchi T, et al. Studies on antifungal activities of sulconazole: 2. Therapeutic effect of the cream formulation on experimental Trichophyton mentagrophytes infection of guinea pig. Chemotherapy (Tokyo) 1984; 32: 485-9
350. Lassus A, Forström S, Salo O. A double-blind comparison of sulconazole nitrate 1% cream with clotrimazole 1% cream in the treatment of dermatophytoses. Br J Dermatol 1989; 108: 195-8
351. Akers WA, Lane A, Lynfield Y, et al. Sulconazole nitrate 1% cream in the treatment of chronic moccasin-type tinea pedis caused by Trichophyton rubrum. J Am Acad Dermatol 1989; 21: 686-9
352. Tanenbaum L, Taplin D, Lavalle C, et al. Sulconazole nitrate cream 1% for treating tinca cruris and corporis. Cutis 1989; 44: 344-7
353. Gip L, Forström S. A double-blind parallel study of sulconazole nitrate 1% cream compared with miconazole 2% cream in dermatophytoses. Mykosen 1983; 26: 231-41
354. Tanenbautn L, Anderson C, Rosenberg MJ, et al. Sulconazole nitrate 1.0 percent cream: a comparison with miconazole in the treatment of tinea pedis and tinea cruris/corporis. Cutis 1982; 30: 105-7
355. Lassus A, Forström S. A double-blind parallel study comparing sulconazole and econazole in the treatment of dermatophytoses. Mykosen 1984; 27: 592-8
356. Tannenbanm L, Anderson C, Rosenberg MJ, et al. 1% sulconazole cream vs. 2% miconazole cream in the treatment of tinea versicolor. Arch Dermatol 1984; 120: 216-9
357. Tanenbaum L, Anderson C, Rosenberg M, et al. A new treatment for cutaneous candidiasis: sulconazole nitrate cream 1% . Int J Dermatol 1983; 22: 318-20
358. Rajan VS, Thirumoorthy T. Treatment of cutaneous candidiasis: a double-blind, parallel comparison of sulconazole nitrate 1% cream and clotrimazole 1% cream. Aust NZ J Med 1983; 24: 33-6
359. Heeres J, Hendrickx R, Van Cutsem J. Antimycotic imidazoles: 6. Synthesis and antifungal properties of terconazole, a novel triazole ketal. J Med Chem 1983; 26: 611-3
360. Cauwenbergh G, Vanden Bossche H. Terconazole: pharmacology of a new antimycotic agent. J Reprod Med 1989; 34: 588-92
361. Van Custeni J, Van Gerven F, Zaman R, et al. Terconazole a new broad spectrum antfunual. Chemotherapy 1983; 29: 322-31
362. Tolman EL, Isaaeson DM, Rosenthale ME, et al. Anticandidal activities of terconazole, a broad-spectrum antimycotic. Antimicrob Agents Chemother 1986; 29: 986-91
363. Vanden Hossche H, Marichal P. Mode of action of anti-Candida drugs: focus on terconazole and other ergosterol biosynthesis inhibitors. Am J Obstet Gynecol 1991; 165: 1193-9
364. Thomason JL. Clinical evaluation of terconazole: United States Experience. J Reprod Med 1989; 34: 597-601
365. Hirsch HA. Clinical evaluation of terconazole: European experience. J Reprod Med 1989; 38: 593-5
366. Kjaeldgaard A. Comparison of terconazole and clotrimazole vaginal tablets in the treatment of vulvovaginal candidosis. Pharmatherapeutica 1986; 4: 525-31
367. Weisberg M. Terconazole: a new antifungal agent for vulvovaginal candidiasis. Clin Ther 1989; 11: 659-68
368. Moebins UM. Influenza-like syndrome after terconazole. Lancet 1988: 11: 936-7
369. Clissold SP, Heel RC. Tioconazole: a review of its antimicrobial activity and therapeutic use in superficial mycoses. Drugs 1986; 31: 29-51
370. Vander Ploeg DE, De Villez RL. A new topical antifungal drug: tioconazole. Int J Dermatol 1984; 23: 681-3
371. Marriott M-S, Baird JRC, Brummer KW, et al. Tioconazole, a new imidazole-antifungal agent for the treatment of dermatomycoses. Dermatologica 1983; 166: 1-7
372. O'Neill Last M, Hendcrson JT, Jevons S. Tioconazole in the treatment of fungal infections of the skin. Dermatologica 1983; 166: 20-33
373. Fredriksson T. Treatment of dermatomycoses with topical tioconazole and miconazole. Dermatologica 1983; 166: 14-9
374. Kashin P, Phyfferoen MC, Gibbs DL. A comparative study of once versus twice daily treatment of dermatophyte and yeast infections with tioconazole (1% cream). J Int Med Res 1985; 13: 85-95
375. del Palacio Hemanz A, Gomez SL, Diez LI. A clinical and mycological assessment of tioconazole solution in the treatment of superficial dermatomycoses. Clin Ther 1987; 9: 333-8
376. Grigoriu D, Grigoriu A. Double-blind comparison of the efficacy, toleration and safety of tioconazole base 1% and econazole nitrate 1% creams in the treatment of patients with fungal infections of the skin or erythrasnia. Dermatologica 1983; 166: 8-13
377. Clayton YM, Hay RJ, McGibbon DH, et al. Double blind comparison of the efficacy of tioconazole and miconazole for the treatment of fungal infection of the skin or erythrasma. Clin Exp Dermatol 1982; 7: 543-9
378. Alchorne MMA, Paschoalick RC, Forjaz MHH. Comparative study of tioconazole and clotrimazole in the treatment of tinea versicolor. Clin Ther 1987; 9: 360-7
379. Hay RJ, Mackie RM, Clayton YM. Tioconazole nail solution -an open study of its efficacy in onychomycosis. Clin Exp Dermatol 1985; 10: 111-5
380. Hay RJ, Clayton YM, Moore MK. A comparison of tioconazole 28% nail solution versus hase as an adjunct to oral griseofulvin in patients with onychomycosis. Clin Exp Dermatol 1987; 12: 175-7
381. Petranyi G, Georgopoulos A, Mieth H. In vivo antimycotic activity of naftifine. Antimicrob Agents Chemother 1981; 19: 390-2
382. Georgopoulos A, Petranyi G, Mieth H, et al. In vitro activity of naftifine, a new antifungal agent. Antimicrob Agents Chemother 1981; 19: 386-9
383. Stütz A. Synthesis and structure-activity correlations within allylamine antimycotics. Ann NY Acad Sci 1988; 544: 46-62
384. Meinicke K, Striegel C, Weidinger G. Treatment of dermatomycoses with naftifine: therapeutic efficacy after once-a-day and twice-a-day application. Mykosen 1984; 27: 608-14
385. Poelmann G. Antimycotic efficacy of naftifine after once-daily application. Mykosen 1985; 28 Suppl. 1: 113-8
386. Effendy I, Friedrich HC. Double-blind, randomized, comparative trial of naftifine solution (once-a-day) and clotrimazole solution (twice-a-day) in the treatment of dermatomycoses. Mykosen 1985; 28 Suppl. 1: 126-34
387. Sowden JM, Allen BR. Naftifine - an antifungal drug with antiinflammatory properties? J Dermatol Treat 1990; 1: 27-8
388. Jones TC. Treatment of dermatomycoses with topically applied allylamines: naftifine and terbinafine. J Dermatol Treat 1990; 1 Suppl. 2: 29-32
389. Solomon BA, Lee WL, Geen SC, et al. Modification of neutrophil functions by naftifine. Br J Dermatol 1993; 128: 393-8
390. Bojanovsky A, Haas P. Antimycotic efficacy of naftifine: double-blind comparative study with bifonazole in tinea pedis. Fortschr Med 1985; 103: 677-9
391. Dobson RL, Bagatell FD, Hickman JG, et al. Naftifine 1% cream in the treatment of tinea cruris and tinea corporis. Drug Invest 1991; 3: 57-9
392. Dobson RL, Binder R, Hickman JG, et al. Once-daily naftifine cream 1% (Naftin) in the treatment of tinea pedis. Clin Trials J 1989; 26: 418-23
393. Gip L, Brundin G. A double-blind, two group multicenter study, comparing naftifine 1% cream with placebo cream in the treatment of tinea cruris. Mykosen 1987; 30 Suppl. 1: 38-41
394. Haas PJ, Tronnier H, Weidinger G. Naftifine in tinea pedis: double-blind comparison with clotrimazole. Mykosen 1987; 30 Suppl. 1: 50-6
395. Jordan RE, Rapini RP, Rex IJ, et al. Once-daily naftifine cream 1% in the treatment of tinea cruris and tinea coporis. int J Dermatol 1990; 29: 441-2
396. Kagawa S. Comparative clinical trial of naftifine and clotrimazole in tinea pedis, tinea cruris and tinea corporis. Mykosen 1987; 30 Suppl. 1: 63-9
397. Klaschka F, Gartmann H, Weidinger G. The antifungal agent naftifine: placebo-controlled therapeutic comparison in tinea pedis. Z Hautkr 1984; 59: 1218-25
398. Meinicke K, Striegel C, Weidinger G. Treatment of dermatomycoses with naftifine: therapeutic efficacy on application once daily and twice daily. Mykosen 1987; 30 Suppl. 1: 98-103
399. Millikan LE, Galen WK, Gewirtzman GB, et al. Naftifine cream 1% versus econazole cream 1% in the treatment of tinea cruris and tinea corporis. J Am Acad Dermatol 1988; 18: 52-6
400. Naftifine Gel Study Group. Naftifine gel in the treatment of tinea pedis: two double-blind, multicenter studies. Cutis 1991; 48: 85-8
401. Naftifine Podiatric Study Group. Naftifine cream 1% versus clotrimazole cream 1% in the treatment of tinea pedis. J Am Podiatr Med Assoc 1990; 80: 314-8
402. Nolting S, Weidinger G. Naftifine in severe dermatomycoses: econazole-controlled therapeutic comparison. Mykosen 1987; 30 Suppl. 1: 70-7
403. Schachner LA, Bagatell FK, Whittington CV, et al. The safety and efficacy of naftifine cream 1% in the treatment of tinea pedis. Adv Ther 1990; 7: 148-52
404. Smith EB, Breneman DL, Griffith RF, et al. Double-blind comparison of naftifine cream and clotrimazole/betamethasone dipropionate cream in the treatment of tinea pedis. J Am Acad Dermatol 1992; 26: 125-7
405. Smith EB, Wiss K, Hanifin JM, et al. Comparison of once- and twice-daily naftifine cream regimens with twice-daily clotrimazole in the treatment of tinea pedis. J Am Acad Dermatol 1990; 22: 1116-7
406. Tronnier H. Inflammatory dermatomycoses: comparative study of naftifine and a combination of a corticosteroid and an imidazole derivative. Mykosen 1987; 30 Suppl. 1: 78-87
407. Evans EGV, James IGV, Seaman RAJ, et al. Does naftifine have anti-inflammatory properties? A double-blind comparative study with 1% clotrimazole/1% hydrocortisone in clinically diagnosed fungal infection of the skin. Br J Dermatol 1993; 129: 437-42
408. Nada M, Hanafi S, Al-Omari H, et al. Naftifine versus miconazole/hydrocortisone in inflammatory dermatophyte infections. Int J Dermatol 1994; 33: 570-2
409. Meyerson MS, Scher RK, Hochman LG, et al. Open-label study of the safety and efficacy of naftifine hydrochloride 1 percent gel in patients with distal subungual onychomycosis of the fingers. Cutis 1993; 51: 205-7
410. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview: part II. J Am Acad Dermatol 1994; 30: 911-33
411. Gupta AK, Shear NH, Sauder DN. New antifungal agents. Cur Opinion Dermatol 1993; 2: 200-6
412. Shear N, Gupta AK. Terbinafine for the treatment of pedal onychomycosis: a foot closer to the promised land of cured nails? Arch Dermatol 1995; 131: 937-42
413. Ryder NS. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol 1992; 126 Suppl. 39: 2-7
414. Hill S, Thomas R, Smith SG, et al. An investigation of the pharmacokinetics of topical terbinafine (Lamisil) 1% crcam. Br J Dermatol 1992; 127: 396-400
415. Topical terbinafine for tinea infections. Med Lett Drugs Ther 1993; 35: 76-8
416. Smith EB, Noppakun N, Newton RC. Clinical trial of topical terbinafine (a new allylamine antifungal): the treatment of tinea pedis. J Am Acad Dermatol 1990; 23: 790-3
417. Savin RC. Treatment of chronic tinea pedis (athlete's foot type) with topical terbinafine. J Am Acad Dermatol 1990; 23: 786-9
418. Savin R, Atton A, Bergstressor PR, et al. Efficacy of terbinafine 1% cream in the treatment of moccasin-type tinea pedis: results of placebo-controlled multicenter trials. J Am Acad Dermatol 1994; 30: 663-7
419. Berman B, Ellis C, Leyden J, et al. Efficacy of a 1-week, twice-daily regimen of terbinafine 1% cream in the treatment of interdigital tinea pedis. J Am Acad Dermatol 1992; 26: 956-60
420. Evans HGV. A comparison of terbinafine (Lamisil) 1% cream given for one week with clotrimazole (Canesten) 1% cream given for four weeks, in the treatment of tinea pedis. Br J Dermatol 1994; 130: 12-4
421. Evans EGV, Dodman B, Williamson PM, et al. Comparison of terbinafine and clotrimazole in treating tinea pedis. BMJ 1993; 307: 645-7
422. Bergstresser PR, Elewski B, Hanifin J, et al. Topical terbinafine and clotrimazole in interdigital tinea pedis: a multicenter comparison of cure and relapse rales with 1- and 4-week treatment regimens. J Am Acad Dermatol 1993; 28: 648-51
423. Elewski B, Bergstresser PR, Hanifin J, et al. Long-term outcome of patients with interdigital tinea pedis treated with terbinafine or clotrimazole. J Am Acad Dermatol 1995; 32: 290-2
424. Ablon G, Rosens T, Spedale J. Comparative efficacy of naftifine. oxiconazole, and terbinafine in short-term treatment of tinea pedis. Clin Trials J 1996; 35 (8): 591-3
425. Nolting S, Bräutigam M. Clinical relevance of the antibacterial activity of terbinafine: a contralateral comparison between 1% terbinafine cream and 0.1% gentamicin sulphate cream in pyoderma. Br J Dermatol 1992; 126 Suppl. 39: 56-60
426. Greer DL, Jolly HW. Treatment of tinea cruris with topical terbinafine. J Am Acad Dermatol 1990; 23: 800-4
427. Millikan LE. Efficacy and tolerability of topical terbinafine in the treatment of tinea cniris. J Am Acad Dermatol 1990; 23: 795-9
428. Evans EGV, Shah JM, Joshipura RC. One-week treatment of tinea corporis and tinea cruris with terbinafine (Lamisil) 1% cream: a placebo-controlled study. J Dermatol Treat 1992; 3: 181-4
429. Zaias N, Berman B, Cordero CN, et al. Efficacy of a 1-week, once-daily regimen of terbinafine 1% cream in the treatment of tinea cruris and tinea corporis. J Am Acad Dermatol 1993; 29: 646-8
430. El-Mansy I, Halim S. Efficacy of one week terbinafine (Lamisil) 1% cream in the treatment of tinea cruris/corporis. Egypt J Dermatol Venereol 1994; 14(1): 99-104
431. Evans KGV, Seaman RAJ, James IGV. Short-duration therapy with terbinafione 1% cream in dermatophyte skin infections. Br J Dermatol 1994; 130: 83-7
432. Meinhof W, Girardi RM, Stracke A. Patient noncompliance in dermatomycosis. Dermatologica 1984; 169 Suppl. 1: 57-66
433. Cooke J. Pharmacoeconomics of antifungal therapy. Bone Marrow Transplant 1994; 14: 518-20
434. Einarson TR, Arikian SR, Shear NH. Pharmacoeconomic analysis of oral drugs in treatment of tinea infections. J Res Pharmaceut Econ 1995; 6 (3): 15-37
435. Einarson TR, Arikian SR, Shear NH. Pharmacoeconomic analysis of oral treatments for onychomycosis: a Canadian study. J Res Pharmaceut Econ 1995; 6 (1): 3-22
436. Einarson TR, Arikian SR, Shear NH. Cost-effective analysis for onychomycosis therapy in Canada from a government perspective. Br J Dermatol 1994; 130: 32-4
437. Arikian SR, Einarson TR, Kobelt-Nguyen G, et al. A multinational
438. Bergman W, Rutten FFH. Oral hehandeling van onychomycose van de teennagels; vergelijking van kosteneffectiviteit van griscofulvine, itraconazol, ketoconazol en terbinafine. Ned Tijdschr Geneeskd 1994; 138: 2346-50
439. Einarson TR, Gupta AK, Shear NH, et al. Clinical and economic factors in the treatment of onychomycosis. Pharmacoeconomics 1996; 9: 307-20
440. Halpern MT, Palmer C. Modeling the cost effectiveness of oral therapy for nail fungus. Am J Man Care 1996; 2: 59-66
441. Marchetti A, Piech CT, McGhan WF, et al. Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model. Clin Ther 1996; 18 (4): 757-77
442. Van Doorslaer FKA, Tormans G, Gupta AK, et al. Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany. Dermatology 1996; 193: 239-44
443. Einarson TR, Oh PI, Gupta AK, et al. Multinational pharmacoeconumic analysis of topical and oral therapies for onychomycosis. J Derm Treatment 1997; 8: 229-35
444. Chren MM. Costs of therapy for dermatophyte infections. J Am Acad Dermatol 1994; 31: S103-6
445. Chren MM, Landefeld S. A cost analysis of topical drug regimens for dermatophyte infections. JAMA 1994; 272: 1922-5
446. Shear NH, Einarson TR, Arikian SR, et al. Pharmacoeconomic analysis of topical treatments for tinea infections. Pharmacoeconomics 1995; 7: 251-67
447. Davis R, Balfour JA. Terbinafine: a pharmacoeconomic appraisal of its use in superficial fungal infections. Pharmacoeconomics 1995; 8: 1-12